Paradoxical activation of alternative pro-survival pathways determines resistance to MEK inhibitors in chronic lymphocytic leukaemia

Yixiang Chen; Sandra Germano; Ghalia Shelmani; Diana Kluczna; Sandrine Jayne; Martin J S Dyer; Salvador Macip

doi:10.1111/bjh.14880

Paradoxical activation of alternative pro-survival pathways determines resistance to MEK inhibitors in chronic lymphocytic leukaemia

Br J Haematol. 2018 Sep;182(6):921-924. doi: 10.1111/bjh.14880. Epub 2017 Aug 2.

Authors

Yixiang Chen^{1

2}, Sandra Germano^{1

2}, Ghalia Shelmani^{1

2}, Diana Kluczna^{1

2}, Sandrine Jayne^{2

3}, Martin J S Dyer^{2

3}, Salvador Macip^{1

2}

Affiliations

¹ Mechanisms of Cancer and Ageing Laboratory, Department of Molecular and Cell Biology, University of Leicester, Leicester, UK.
² Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK.
³ Department of Cancer Studies, University of Leicester, Leicester, UK.

PMID: 28771685
DOI: 10.1111/bjh.14880

No abstract available

Keywords: AKT; CLL; CRAF; MAPK; MEK inhibitors.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Drug Resistance, Neoplasm*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
MAP Kinase Signaling System / drug effects*
Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors / pharmacology
Signal Transduction
Tumor Cells, Cultured
raf Kinases / metabolism

Substances

Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors
raf Kinases

Grants and funding

MC_U132670597/MRC_/Medical Research Council/United Kingdom